Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis

Andrea Luengas-Martinez, Jonathan Hardman-Smart, Ralf Paus, Helen S. Young

Research output: Contribution to journalArticle

Abstract

Vascular endothelial growth factor-A (VEGF-A), the main angiogenic mediator, plays a critical role in the pathogenesis of several inflammatory immune-mediated diseases, including psoriasis. Even though anti-angiogenic therapies, such as VEGF inhibitors, are licensed for the treatment of various cancers and eye disease, VEGF-targeting interventions are not part of current psoriasis therapy. In this viewpoint essay, we argue that the existing preclinical research evidence on the role of VEGF-A in the pathogenesis of psoriasis as well as clinical observations in patients who have experienced psoriasis remission during oncological anti-VEGF-A therapy strongly suggests to systematically explore angiogenesis targeting also in the management of psoriasis. We also point out that some psoriasis therapies decrease circulating levels of VEGF-A and normalise the psoriasis-associated vascular pathology in the papillary dermis of plaques of psoriasis and that a subset of patients with constitutionally high levels of VEGF-A may benefit most from the anti-angiogenic therapy we advocate here. Given that novel, well-targeted personalised medicine therapies for the development of psoriasis need to be developed, we explore the hypothesis that VEGF-A and signalling through its receptors constitute a promising target for therapeutic intervention in the future management of psoriasis.

Original languageEnglish (US)
Pages (from-to)687-698
Number of pages12
JournalExperimental dermatology
Volume29
Issue number8
DOIs
StatePublished - Aug 1 2020

Keywords

  • angiogenesis
  • bevacizumab
  • personalised medicine
  • psoriasis
  • vascular endothelial growth factor-A

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Fingerprint Dive into the research topics of 'Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis'. Together they form a unique fingerprint.

  • Cite this